Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evogene ( (EVGN) ) has shared an update.
On July 8, 2025, Evogene Ltd. announced the completion of a significant transaction involving the sale of most of the activities of its subsidiary, Lavie Bio Ltd., to ICL Group Ltd. This transaction includes the transfer of Lavie Bio’s proprietary technologies and personnel to ICL, while retaining existing strategic partnerships and agreements. This move aligns with Evogene’s strategy to unlock the value of its subsidiaries and is expected to enhance ICL’s capabilities in the ag-biologicals sector, advancing sustainable agricultural solutions.
The most recent analyst rating on (EVGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene faces significant financial challenges, with weak financial performance being the primary concern. While there are positive signs in technical analysis and strategic actions, such as expense reduction and acquisitions, the company’s valuation and earnings outlook remain problematic. Overall, the stock score reflects a cautious stance due to these persistent risks.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. is a computational biology company that leverages advanced artificial intelligence and predictive biology to innovate life-science product development. The company has developed three technological engines – MicroBoost AI, ChemPass AI, and GeneRator AI – focusing on microbes, small molecules, and genetic elements, respectively. Evogene’s subsidiaries utilize these technologies to develop products in various sectors, including human microbiome-based therapeutics, ag-chemicals, and ag-biologicals.
Average Trading Volume: 2,239,711
Technical Sentiment Signal: Sell
Current Market Cap: $11.5M
See more insights into EVGN stock on TipRanks’ Stock Analysis page.